ADVERTISEMENT

404

Not Found

Is this what you were looking for?

tag child care industry pharma

Concerns over Efficacy and Cost of Muscle Wasting Treatments
Ruth Williams | Nov 11, 2020 | 5 min read
Two new medications for treating a rare and deadly neuromuscular disease have high prices and questionable efficacies, say scientists.
How Orphan Drugs Became a Highly Profitable Industry
Diana Kwon | May 1, 2018 | 10+ min read
Government incentives, advances in technology, and an army of patient advocates have spun a successful market—but abuses of the system and exorbitant prices could cause a backlash.
Meetings Of Scientific Societies: A Time For Changes?
August Epple | Sep 14, 1997 | 7 min read
Ever since I learned about the birds and the bees, I asked myself: Why would a woman want to bear a second child? Over the years, I also began to wonder why anyone would want to organize the meeting of a scientific society for a second time. After all, there are similarities between the two processes: an exciting idea leading to foreplay (development of the preliminary program), joyful activity with a climax (meeting), morning sickness (retrieval of manuscripts), birth (publication of the proce
Sequencing Stakes: Celera Genomics Carves Its Niche
Ricki Lewis | Jul 18, 1999 | 8 min read
J. Craig Venter is no stranger to contradiction and controversy. He seems to thrive on it. In 1991, when the National Institutes of Health was haggling over patenting expressed sequence tags (ESTs)--a shortcut to identifying protein-encoding genes--Venter the inventor accepted a private offer to found The Institute for Genomic Research (TIGR) in Rockville, Md. TIGR would discover ESTs and give most of them to a commercial sibling, Human Genome Sciences (HGS), to market. ESTs are now a standard
Updated July 9
Track COVID-19 Vaccines Advancing Through Clinical Trials
The Scientist | Apr 7, 2020 | 10+ min read
Find the latest updates in this one-stop resource, including efficacy data and side effects of approved shots, as well as progress on new candidates entering human studies.
Top Ten Innovations 2010
Megan Scudellari | Dec 1, 2010 | 10+ min read
By The Scientist Staff Top Ten Innovations 2010 Innovative products that have the life science community buzzing. As the global economy continues to pull out of its recent precipitous nosedive, one mantra rings true from Beijing to Boston—innovation can save us. If developing interesting new technologies and products really is the lifeblood of economic health, then the life sciences industry is innovation’s beating heart. The Scientist rec
Change Broker
Yvonne Greenstreet | May 1, 2009 | 10 min read
Change Broker GlaxoSmithKline is overhauling the drug discovery and development process, one more time. The crucial difference: putting big decisions in the hands of our scientists. By Yvonne Greenstreet T. Walenta lenty has been said about the problems of the pharmaceutical industry and the need to reinvigorate the model. But how do you go about it? What changes can be made that will have notable improvement without risking the cor
The Little Cell That Could
Megan Scudellari | Jul 1, 2012 | 7 min read
Critics point out that cell therapy has yet to top existing treatments. Biotech companies are setting out to change that—and prove that the technology can revolutionize medicine.
Innovation Imperiled
Richard Gallagher | Jan 1, 2009 | 3 min read
US healthcare needs radical revision, but we can't wipe out innovation in the process.
Tricky Trials
Mary Beth Aberlin | Mar 1, 2012 | 3 min read
Studies on safety, efficacy, or dosing of drugs in children, or on nutritional supplements, are not run-of-the-mill.

Run a Search

ADVERTISEMENT